Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)

被引：0
|
作者：
Liu, S. V. [1 ]
De Braud, F. [2 ]
Drilon, A. [3 ]
Doebele, R. C. [4 ]
Patel, M. R. [5 ]
Cho, B. C. [6 ]
Ahn, M. J. [7 ]
Chiu, C. H. [8 ]
Farago, A. F. [9 ]
Goto, K. [10 ]
Lee, J. [7 ]
Ohe, Y. [11 ]
Ou, S. H. I. [12 ]
Cassier, P. [13 ]
Tan, D. S. W. [14 ]
Otterson, G. A. [15 ,16 ]
Veronese, L. [17 ]
Osborne, S. [17 ]
Simmons, B. [18 ]
Siena, S. [19 ,20 ]
机构：
[1] Georgetown Univ, Washington, DC 20057 USA
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Univ Colorado, Aurora, CO USA
[5] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA
[6] Yonsei Canc Ctr, Seoul, South Korea
[7] Sungkyunkwan Univ, Div Hematol Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea
[8] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Natl Canc Ctr, Tokyo, Japan
[12] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[13] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[14] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[15] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[16] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA
[17] F Hoffmann La Roche Ltd, Basel, Switzerland
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[20] Metropolitano Niguarda, Niguarda Canc Ctr, Grande Osped, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 04期
关键词：
D O I：
10.1016/j.annonc.2021.01.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：577 / 577
页数：1
相关论文
共 50 条
  • [21] How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
    Ekman, Simon
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2535 - 2544
  • [22] Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
    Frehner, Lorenz
    Haefliger, Simon
    Cerciello, Ferdinando
    Grob, Tobias
    Schmid, Sabine
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 871 - 877
  • [23] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
    Drilon, Alexander
    Siena, Salvatore
    Dziadziuszko, Rafal
    Barlesi, Fabrice
    Krebs, Matthew G.
    Shaw, Alice T.
    de Braud, Filippo
    Rolfo, Christian
    Ahn, Myung-Ju
    Wolf, Juergen
    Seto, Takashi
    Cho, Byoung Chul
    Patel, Manish R.
    Chiu, Chao-Hua
    John, Thomas
    Goto, Koichi
    Karapetis, Christos S.
    Arkenau, Hendrick-Tobias
    Kim, Sang-We
    Ohe, Yuichiro
    Li, Yu-Chung
    Chae, Young K.
    Chung, Christine H.
    Otterson, Gregory A.
    Murakami, Haruyasu
    Lin, Chia-Chi
    Tan, Daniel S. W.
    Prenen, Hans
    Riehl, Todd
    Chow-Maneval, Edna
    Simmons, Brian
    Cui, Na
    Johnson, Ann
    Eng, Susan
    Wilson, Timothy R.
    Doebele, Robert C.
    LANCET ONCOLOGY, 2020, 21 (02): : 261 - 270
  • [24] Targeted therapy of RET fusion-positive non-small cell lung cancer
    Shen, Zixiong
    Qiu, Binxu
    Li, Lin
    Yang, Bo
    Li, Guanghu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy
    Haratake, Naoki
    Seto, Takashi
    CLINICAL LUNG CANCER, 2021, 22 (01) : 1 - 5
  • [26] Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer
    Wang, Jialei
    Zhao, Xinmin
    Zhang, Xin
    Chen, Hanlin
    Bao, Hairong
    Wu, Xianghua
    Wang, Huijie
    Bao, Hua
    Pang, Jiao
    Wang, Sha
    Tang, Haimeng
    Tang, Shiting
    Wu, Xue
    Shao, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
    Dziadziuszko, Rafal
    Krebs, Matthew G.
    De Braud, Filippo
    Siena, Salvatore
    Drilon, Alexander
    Doebele, Robert C.
    Patel, Manish R.
    Cho, Byoung Chul
    Liu, Stephen V.
    Ahn, Myung-Ju
    Chiu, Chao-Hua
    Farago, Anna F.
    Lin, Chia-Chi
    Karapetis, Christos S.
    Li, Yu-Chung
    Day, Bann-mo
    Chen, David
    Wilson, Timothy R.
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1253 - +
  • [28] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (vol 21, pg 261, 2020)
    Drilon, A.
    Siena, S.
    Dziadziuszko, R.
    LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
  • [29] A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
    Yang, J.
    Zhou, J.
    Li, M.
    Zhang, Z-Y.
    Cheng, Y.
    Chu, D. H.
    Pan, H.
    Wang, B.
    Chen, G.
    Wang, K.
    Jiang, L.
    Hu, Y.
    Shi, J.
    Hui, A-M.
    Zhou, Y.
    Wu, Z.
    Sun, J.
    Tan, Y.
    Xiang, X.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2022, 33 : S1595 - S1595
  • [30] SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
    Horiike, Atsushi
    Takeuchi, Kengo
    Uenami, Takeshi
    Kawano, Yuko
    Tanimoto, Azusa
    Kaburaki, Kyohei
    Kobayashi, Hiroshi
    Gyotoku, Hiroshi
    Nishizawa, Hironari
    Tambo, Yuichi
    Nakatomi, Katsumi
    Yanagitani, Noriko
    Ohyanagi, Fumiyoshi
    Hagiwara, Sachiko
    Motoi, Noriko
    Ishikawa, Yuichi
    Horai, Takeshi
    Nishio, Makoto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S898 - S898
12345